Human infection with Fusobacterium necrophorum (Necrobacillosis), with a focus on Lemierre's syndrome.
Human infection with Fusobacterium necrophorum usually involves F. necrophorum subsp. funduliforme rather than F. necrophorum subsp. necrophorum, which is a common pathogen in animals. Lemierre's syndrome, or postanginal sepsis, is the most common life-threatening manifestation. Tonsillitis is followed by septic thrombophlebitis of the internal jugular vein and then a septicemia with septic emboli in lungs and other sites. Recent evidence suggests that F. necrophorum can be limited to the throat and cause persistent or recurrent tonsillitis. F. necrophorum is unique among non-spore-forming anaerobes, first for its virulence and association with Lemierre's syndrome as a monomicrobial infection and second because it seems probable that it is an exogenously acquired infection. The source of infection is unclear; suggestions include acquisition from animals or human-to-human transmission. Approximately 10% of published cases are associated with infectious mononucleosis, which may facilitate invasion. Recent work suggests that underlying thrombophilia may predispose to internal jugular vein thrombophlebitis. Lemierre's syndrome was relatively common in the preantibiotic era but seemed to virtually disappear with widespread use of antibiotics for upper respiratory tract infection. In the last 15 years there has been a rise in incidence, possibly related to restriction in antibiotic use for sore throat.
Riordan
Terry
T
Microbiology Department, Royal Devon & Exeter Foundation Trust, Exeter, United Kingdom. terry.riordan@rdeft.nhs.uk
D000293:Adolescent; D000328:Adult; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005674:Fusobacterium Infections / Q000453:epidemiology / Q000382:microbiology / Q000503:physiopathology / Q000628:therapy; D005675:Fusobacterium necrophorum / Q000187:drug effects / Q000472:pathogenicity*; D006801:Humans; D008297:Male; D013577:Syndrome
D000900:Anti-Bacterial Agents